{"id":62396,"date":"2025-12-22T22:05:54","date_gmt":"2025-12-22T21:05:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/"},"modified":"2025-12-22T22:05:54","modified_gmt":"2025-12-22T21:05:54","slug":"forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/","title":{"rendered":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules"},"content":{"rendered":"
\n

DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com<\/a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.<\/p>\n

\nIn accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of an equity award in the form of options to purchase a total of 75,000 shares of common stock to a new non-executive employee as a material inducement to such individual accepting employment with the Company. The option award shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee\u2019s employment commencement date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to the individual\u2019s continuous employment through each vesting date.<\/p>\n

\nThe inducement award was made under Forte\u2019s 2020 Inducement Equity Incentive Plan and related award agreements.<\/p>\n

\nAbout Forte<\/b><\/p>\n

\nForte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.<\/p>\n

\nSource: Forte Biosciences, Inc.<\/p>\n

Contacts<\/b> <\/p>\n

\nForte Biosciences, Inc.
\n
Paul Wagner, CEO
\n
investors@fortebiorx.com<\/a><\/p>\n

\nLifeSci Advisors
\n
Mike Moyer, Managing Director
\n
mmoyer@lifesciadvisors.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62396","6":"format-standard","7":"category-industry"},"yoast_head":"\nForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T21:05:54+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules\",\"datePublished\":\"2025-12-22T21:05:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/\"},\"wordCount\":236,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/\",\"name\":\"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2025-12-22T21:05:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend","og_description":"DALLAS–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-22T21:05:54+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules","datePublished":"2025-12-22T21:05:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/"},"wordCount":236,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/","url":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/","name":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2025-12-22T21:05:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/forte-biosciences-inc-reports-inducement-grant-under-nasdaq-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62396"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62396\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}